

# Building a Health System that can Ensure Healthy Longevity in an Era of 100 Year Lifespans

## Three Concepts to Guide Policy

### 3 Concepts

#### Concept 1

It is important to seek out ways to make the healthcare system more effective and efficient.



#### Concept 2

Money is not “spent” on the healthcare system, it is invested.

Implement these concepts by promoting:

- ✓ Measures to increase spending efficiency
- ✓ Regulatory Science measures to reduce the costs of R&D and improve market access
- ✓ The further development of push and pull incentives for innovation
- ✓ Measures to strengthen healthcare data infrastructure to better inform policy debates
- ✓ Innovative financing mechanisms to help fund new treatments and health interventions
- ✓ Polymaking that reflects patient values


#### Concept 3

The purpose of the healthcare system should not just be to cure, but to increase healthy life expectancy.



# Outline of Policy Options

Health and Global Policy Institute (HGPI) formed an expert taskforce in FY2019 to debate the future of the health system. The chart below outlines the discussion that took place in that taskforce.



Note: Please see the taskforce's report for a detailed description of each policy option.

\*Health Technology Assessment

\*\*Personal Health Records

## Taskforce members (alphabetical order by last name)

- Mamoru Ichikawa** (Principal Program Director, Japan Broadcasting Corporation (NHK))
- Ataru Igarashi** (Associate Professor, Unit of Public Health and Preventive Medicine, Yokohama City University of Medicine)
- Satoshi Imamura** (Vice-President, Japan Medical Association)
- Isao Kamae** (Project Professor, Graduate School of Public Policy, The University of Tokyo)
- Toshio Nagase** (Government Affairs Japan, Gilead Science K.K.)
- Hiroshi Nakamura** (Professor, Graduate School of Business Administration, Keio University)
- Kazumasa Oguro** (Professor, Faculty of Economics, Hosei University)
- Naokazu Saito** (Director, Policy Intelligence Department, Janssen Pharmaceutical K.K.)
- Naomi Sakurai** (President, Cancer Solutions Co., Ltd.)
- Eiko Shimizu** (Project Associate Professor, ITHC, Graduate School of Pharmaceutical Sciences, The University of Tokyo)
- Mitsuo Umezu** (Director, Institute for Medical Regulatory Science, Waseda University)
- Hirokazu Yoshii** (Special Advisor to the President, Health Insurance Claims Review & Reimbursement Services)



## Health and Global Policy Institute

Grand Cube 3F, Otemachi Financial City,  
 Global Business Hub Tokyo 1-9-2,  
 Otemachi, Chiyoda-ku, Tokyo, 100-0004 Japan  
 Tel: 03-4243-7156 Fax: 03-4243-7378 E-mail: info@hgpi.org

This project was carried out using the Chatham House Rule, which prohibits the attribution of any specific remark to any specific speaker. This document and the taskforce's report were compiled by HGPI and contributing authors, and the opinions expressed within should not be construed to represent the opinion of any one project participant.